Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Actiphage – unique role in TB testing

One of the greatest challenges for tuberculosis (TB) biomarkers and diagnostics is to distinguish between latent TB (LTBI) and incipient TB. Incipient TB does not have clinical symptoms, but will likely progress to active disease. Incipient TB can remain stable for years. Without treatment, inactive TB can become active TB disease at any time. Actiphage may play roles in TB screening of LTBI individuals and management of TB drug therapy.

Detection of Active Mycobacteria Across the Spectrum of TB Infection

  • There are currently no reliable biomarkers for the detection of incipient TB, despite research to identify new TB biomarkers and diagnostics.
  • Immune-based diagnostics provide evidence of an immune memory response to TB infection rather than confirming the presence of active organisms.
  • Traditional PCR-based methods do not discriminate between active, viable and non-viable mycobacterium tuberculosis.
  • Actiphage is the only blood-based test that combines phage technology to detect only active, disease-causing mycobacteria with traditional qPCR methods.
  • Actiphage does not require cultivation to detect bacteria and has higher accuracy and faster turnaround times.
Diagnostics comparison diagram

Tuberculosis Drug Treatment Management

Preventive Drug Therapy

  • Current immune-based LTBI diagnostics (TST, IGRA) have a poor positive predictive value (PPV), so targeted testing and treatment is only recommended for high risk groups.
  • Actiphage is designed to detect incipient TB and disease progression, which may allow for scale-up of preventive treatment beyond the current risk groups.
  • Actiphage is a blood-based test designed for screening of LTBI in populations with an easily collected sample.
  • Actiphage may create a significant opportunity for LTBI preventive therapy drug development.
Latent TB to incipient TB diagram

TB Drug Monitoring

  • Actiphage has the potential to be a diagnostics marker for drug response and predictors of relapse.
  • Actiphage provides confirmation of active Mtb and may overcome certain barriers to LTBI therapy such as uncertainty of diagnosis.
Active TB to eliminated diagram

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!